Skip to main content

What are you looking for?

Write the name, title or any keyword related to what you are looking for and select which content category it belongs to.

A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-969 in adult subjects with metastatic castration-resistant prostate cancer.

  • Protocol code: M24-742
  • EudraCT code: _
  • Pathology: Tumors
  • Principal investigator:  Valderrama Rodríguez, Angelica
  • Service: Sense classificar
  • Phase: Fase I
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo aleatorizado en fase III de rilvegostomig en combinación con fluoropirimidina y trastuzumab deruxtecán frente a trastuzumab, quimioterapia y pembrolizumab para el tratamiento de primera línea del cáncer gástrico HER2-positivo

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (Ideate-Esophageal01)

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo con una extensión abierta para evaluar la eficacia, la seguridad y la tolerabilidad de Atogepant para el tratamiento preventivo de la migraña menstrual

  • Protocol code: M24-859
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Pozo Rosich, Patricia
  • Research group:  Cefalea i dolor neurològic
  • Service: Neurologia
  • Phase: Phase III
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo en fase III abierto, aleatorizado y de no inferioridad de nivolumab subcutáneo frente a nivolumab intravenoso en participantes con carcinoma renal de células claras metastásico o avanzado que hayan recibido tratamiento sistémico anterior

  • Protocol code: CA209-67T
  • EudraCT code: 2020-003655-15
  • Pathology: Tumors
  • Principal investigator:  González Rodríguez, Macarena
  • Service: Oncology
  • Phase: Phase III
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Portal)

  • Protocol code: GR40549
  • EudraCT code: 2020-004427-16
  • Pathology: Malalties de l’ull i dels seus annexos
  • Principal investigator:  García Arumí, José
  • Research group:  Oftalmologia
  • Service: Oftalmologia
  • Phase: Phase III
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

An Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe

  • Protocol code: KOR-PED-202
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Ariceta Iraola, Gema
  • Research group:  Fisiopatologia renal
  • Service: Nefrologia Pediàtrica
  • Phase: Fase II
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

  • Protocol code: BLU-808-1201
  • EudraCT code: No aplica
  • Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified
  • Principal investigator:  Labrador Horrillo, Moisés
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Phase II
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Un estudio de Fase III, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar el efecto de AZD0780 sobre los eventos cardiovasculares adversos mayores en pacientes con enfermedad cardiovascular arterioesclerótica (ECVA) establecida o en alto riesgo de un primer evento de ECVA.

  • Protocol code: D7960C00015
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema circulatori
  • Principal investigator:  Molina Cateriano, Carlos
  • Research group:  Recerca en ictus
  • Service: Neurology
  • Phase: Phase III
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Professionals

Sandra Marmol Niubo

I am a Research Technician with expertise in cell culture.
Year
2025
Títol Complet
Servicio de creación y desarrollo de cursos online en el ámbito de ciencias de la salud a cargo del Proyecto 101060102 "GIMM-CARE: boosting clinical research for the benefit of society", destinado al Grupo de Estrategia Externa de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
CREACIÓN Y DESARROLLO CURSOS ONLINE CIENCIAS SALUD
Codi
24987390
Data publicació
Year
2025
Títol Complet
Contratación del servicio de un profesional licenciado en psicología para valorar pacientes afectos de enfermedades lisosomales que participan en los ensayos DNL-008, AZA-001 y UX-111 de la Unidad de Investigación en Neurología Pediátrica, de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) financiado por los promotores Denali, Ultragenyx y Azafaros.
Expedient
EVALUACIONES NEUROPSICOLÓGICAS
Codi
24987316
Data publicació
Year
2025
Títol Complet
Acuerdo Marco es la selección de cuatro (4) consultores por los servicios de consultoría y asistencia técnica destinados a los proyectos de investigación, valorización y transferencia de la Fundació Hospital Universitari Vall Hebron-Institut de Recerca (VHIR)
Expedient
ACUERDO MARCO S. CONSULTORIA Y ASIST. TÉCNICA
Codi
24987317
Data publicació

Professionals

Maria Angeles Crespo Cuadrado

I work as international project manager in the Pre-Award team of the Competitive Research Unit at the Vall d’Hebron Research Institute (VHIR). My main role is to advise VHIR principal investigators in the identification of competitive international calls relevant to their research lines, promoting t